PRINCETON, N.J.--(BUSINESS WIRE)--A first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of GE Healthcare’s isosmolar contrast media (CM) iodixanol (Visipaque) and the low-osmolar CM iopromide in select patients concluded iodixanol is associated with lower incidence of contrast-induced neuropathy (CIN) and cardiovascular events (CV) than iopromide, when used in patients with chronic kidney disease. The study is published in December’s Catheterization and Cardiovascular Interventions, a leading scientific journal that covers current hot topics in interventional imaging.
